goglides.dev
ResearchFinanceTechCompaniesDiscussion
Search
Sign inJoin
goglidesgoglides.devSocial learning for Finance and Tech.
TermsPrivacyDisclaimerModerationAcceptable UseDMCAContact
Company / Finance

Vertex Pharmaceuticals Incorporated

VRTX · UNKNOWN

Vertex reported FY2025 revenue of $12.00 billion and Q1 2026 revenue of $2.99 billion, with the official record tying the thesis to cystic-fibrosis durability, pipeline diversification, cash conversion and R&D execution.

Ask Question
Coverage BootstrapNASDAQVertex Pharmaceuticals IncorporatedVRTX
OverviewFinancialsResearchTimelineCompareValuationScorecardDiscussion
Latest ReportJul 22, 2026Vertex: the CF cash engine still has to prove the next pipeline legView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
Coverage Bootstrap
Clear tags
Latest Thesis

Vertex: the CF cash engine still has to prove the next pipeline leg

Vertex reported FY2025 revenue of $12.00 billion and Q1 2026 revenue of $2.99 billion, with the official record tying the thesis to cystic-fibrosis durability, pipeline diversification, cash conversion and R&D execution.

Jul 22, 20265 minSlides available
Read reportOpen slidesDiscussion (0)
Vertex Pharmaceuticals Incorporatedthe CF cash engine still has to prove the next pipeline legJul 22, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Vertex: the CF cash engine still has to prove the next pipeline legVertex reported FY2025 revenue of $12.00 billion and Q1 2026 revenue of $2.99 billion, with the official record tying the thesis to cystic-fibrosis durability, pipeline diversification, cash conversion and R&D execution.NASDAQJul 22, 20265 minReadSlides

Report Sources

No source records are attached to the current company reports.

FollowAdd to Watchlist